Anzupgo is the first topical pan-Janus kinase (JAK) inhibitor to be approved in Switzerland specifically for moderate to ...

Danish dermatology specialist LEO Pharma today announced that Swissmedic, Switzerland’s national regulatory agency for ...

At the OCT DACH conference, experts shared how EU laws, digitalisation, and more, are impacting trials in the DACH region and ...

CN Bio, a leading provider of Organ-on-a-chip Systems and solutions that accelerate drug discovery and development workflows, today announced the launch of its PhysioMimix® Bioavailability assay kit: ...

NOT FOR UK USE ? NOT INTENDED FOR UK MEDIA LEO Pharma A/S, a global leader in medical dermatology, today announced that Swissmedic, Switzerland's national regulatory agency for approving and ...

Thanks to our increase in capacity and ongoing launch expansion. In the third quarter, CARVYKTI became commercially available ...

it involves the regulatory authorities of Australia (Therapeutic Goods Administration (TGA)), Canada (Health Canada), Singapore (Health Sciences Authority (HSA)), Switzerland (Swissmedic), and ...

“Apart from Swissmedic, this is longer than other regulatory agencies.” By contrast, the US Food and Drug Administration (FDA) had a median approval time of 244 days, Health Canada had a ...

Announced plans for new, state-of-the-art cell therapy R&D facility in Philadelphia Cash and cash equivalents, and time deposits of $1.2 billion, as of September 30, 2024, which Legend Biotech ...

AdvaMed has reported that its member companies have provided $26.8 million in medical supplies, along with $4.1 million in cash donations.